Cancer is one of the greatest challenges of human health and life quality. In addition to surgical, chemical and radiation therapeutics, activation of the immune system was shown to be powerful to control cancers. Currently, it is believed that there are extensive interactions between cancer cells and immune cell environment in a solid tumor. The innate immune cells (NK cells, DCs, macrophages, and gamma delta T cells) and adaptive immune cells, especially Ag-specific CD8 T cells, are both exerting critical roles in controlling the tumor formation and growth. There is animal, and clinical data showing that drugs either stimulating the anti-tumor immunity (e.g. Zoledronic acid for stimulating gamma delta T cells), or inhibitors of the immuno-checkpoints CTLA-4 or PD-1 of CD8 T cells, are significantly refining the cancer therapy field. Moreover, there are complicated cross-regulations among immune cells, contributing to the outcome of cancer. Thus, detailed understanding of the tumor microenvironment and exploring new therapeutic targets in cancer immunity are important to improve the therapeutical strategies.
This Research Topic will summarize the current understanding of tumor immunity, with underlying molecular mechanisms. Moreover, it will also further address the interactions among immune cells subtypes, which are important for successful cancer immune surveillance.
We welcome authors to submit Review and Original research articles focusing on, but not limited to, the following subtopics:
1. Lymphocyte signaling pathways including new sensors, activation mechanisms, and effector molecules in tumor immunity;
2. Interaction between tumor cells and immune cells;
3. New therapies targeting immunity in cancer.
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic.
Cancer is one of the greatest challenges of human health and life quality. In addition to surgical, chemical and radiation therapeutics, activation of the immune system was shown to be powerful to control cancers. Currently, it is believed that there are extensive interactions between cancer cells and immune cell environment in a solid tumor. The innate immune cells (NK cells, DCs, macrophages, and gamma delta T cells) and adaptive immune cells, especially Ag-specific CD8 T cells, are both exerting critical roles in controlling the tumor formation and growth. There is animal, and clinical data showing that drugs either stimulating the anti-tumor immunity (e.g. Zoledronic acid for stimulating gamma delta T cells), or inhibitors of the immuno-checkpoints CTLA-4 or PD-1 of CD8 T cells, are significantly refining the cancer therapy field. Moreover, there are complicated cross-regulations among immune cells, contributing to the outcome of cancer. Thus, detailed understanding of the tumor microenvironment and exploring new therapeutic targets in cancer immunity are important to improve the therapeutical strategies.
This Research Topic will summarize the current understanding of tumor immunity, with underlying molecular mechanisms. Moreover, it will also further address the interactions among immune cells subtypes, which are important for successful cancer immune surveillance.
We welcome authors to submit Review and Original research articles focusing on, but not limited to, the following subtopics:
1. Lymphocyte signaling pathways including new sensors, activation mechanisms, and effector molecules in tumor immunity;
2. Interaction between tumor cells and immune cells;
3. New therapies targeting immunity in cancer.
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic.
